# Esomeprazole for Prevention of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs

> **NCT00241514** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 334 (—)

## Conditions studied

- GERD

## Interventions

- **DRUG:** Esomeprazole

## Key facts

- **NCT ID:** NCT00241514
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-02
- **Primary completion:** 2003-02
- **Final completion:** 2003-02
- **Target enrollment:** 334 (—)
- **Last updated:** 2011-01-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00241514

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00241514, "Esomeprazole for Prevention of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00241514. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*